ランキング
お知らせ
ログイン
ランキング
お知らせ
ログイン
雑誌詳細
文献概要
今月の特集 免疫・アレルギー性肺疾患と検査 疾患各論
膠原病に伴う肺障害
著者： 榎本紀之12
所属機関： 1浜松医科大学内科学第2講座 2浜松医科大学保健管理センター
ページ範囲：P.708 - P.716
Point
●膠原病（CTD）では，間質性肺疾患（ILD）のみでなく気道病変，血管病変など多彩な肺病変を合併し，特にILDと肺高血圧症（PH）の合併が予後を悪化させる．
●全身性強皮症（SSc）や多発性筋炎/皮膚筋炎（PM/DM），混合性結合組織病（MCTD）においてILDの合併率が高い．
●CTD診断時には，胸部CTや聴診などによるILDの早期発見，早期治療開始が重要であり，予後を改善する．
●CTD関連のILDの診断には，日和見感染や薬剤性肺障害の鑑別診断が必要である．
●膠原病（CTD）では，間質性肺疾患（ILD）のみでなく気道病変，血管病変など多彩な肺病変を合併し，特にILDと肺高血圧症（PH）の合併が予後を悪化させる．
●全身性強皮症（SSc）や多発性筋炎/皮膚筋炎（PM/DM），混合性結合組織病（MCTD）においてILDの合併率が高い．
●CTD診断時には，胸部CTや聴診などによるILDの早期発見，早期治療開始が重要であり，予後を改善する．
●CTD関連のILDの診断には，日和見感染や薬剤性肺障害の鑑別診断が必要である．
参考文献
1）日本呼吸器学会，日本リウマチ学会合同膠原病に伴う間質性肺疾患診断・治療指針2020作成委員会（編）：膠原病に伴う間質性肺疾患診断・治療指針2020，日本呼吸器学会，2020
2）Cano-Jiménez E, Vázquez Rodríguez T, Martín-Robles I, et al：Diagnostic delay of associated interstitial lung disease increases mortality in rheumatoid arthritis. Sci Rep 11：9184，2021
3）Fischer A, du Bois R：Interstitial lung disease in connective tissue disorders. Lancet 380：689-698，2012
4）Patterson KC, Shah RJ, Porteous MK, et al：Interstitial Lung Disease in the Elderly. Chest 151：838-844，2017
5）Joy GM, Arbiv OA, Wong CK, et al：Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis. Eur Respir Rev 32：220210，2023
6）Oldham JM, Adegunsoye A, Valenzi E, et al：Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir J 47：1767-1775，2016
7）Enomoto N, Suda T, Kato M, et al：Quantitative analysis of fibroblastic foci in usual interstitial pneumonia. Chest 130：22-29，2006
8）Natsuizaka M, Chiba H, Kuronuma K, et al：Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med 190：773-779，2014
9）Park IN, Kim DS, Shim TS, et al：Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest 132：214-220，2007
10）Suda T, Kaida Y, Nakamura Y, et al：Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir Med 103：846-853，2009
11）Enomoto N, Naoi H, Mochizuka Y, et al：Frequency, proportion of PF-ILD, and prognostic factors in patients with acute exacerbation of ILD related to systemic autoimmune diseases. BMC Pulm Med 22：387，2022
12）Park JW, Curtis JR, Choi SR, et al：Risk-Benefit Analysis of Primary Prophylaxis Against Pneumocystis Jirovecii Pneumonia in Patients With Rheumatic Diseases Receiving Rituximab. Arthritis Rheumatol 75：2036-2044，2023
13）Tyndall AJ, Bannert B, Vonk M, et al：Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69：1809-1815，2010
14）Distler O, Assassi S, Cottin V, et al：Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur Respir J 55：1902026，2020
15）Strollo D, Goldin J：Imaging lung disease in systemic sclerosis. Curr Rheumatol Rep 12：156-161，2010
16）Wongkarnjana A, Ryerson CJ：Progressive fibrosing interstitial lung disease: we know it behaves badly, but what does that mean?. Eur Respir J 55：2000894，2020
17）Goh NS, Desai SR, Veeraraghavan S, et al：Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 177：1248-1254，2008
18）Distler O, Highland KB, Gahlemann M, et al：Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med 380：2518-2528，2019
19）Yamasaki Y, Yamada H, Ohkubo M, et al：Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. J Rheumatol 38：1636-1643，2011
20）Takato H, Waseda Y, Watanabe S, et al：Pulmonary manifestations of anti-ARS antibody positive interstitial pneumonia--with or without PM/DM. Respir Med 107：128-133，2013
21）Tanizawa K, Handa T, Nakashima R, et al：HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med 105：1380-1387，2011
22）Fujisawa T, Hozumi H, Kono M, et al：Prognostic factors for myositis-associated interstitial lung disease. PLoS One 9：e98824，2014
23）Hozumi H, Fujisawa T, Nakashima R, et al：Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. Respir Med 121：91-99，2016
24）Kurita T, Yasuda S, Oba K, et al：The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology (Oxford) 54：1536，2015
25）Fujisawa T, Hozumi H, Kamiya Y, et al：Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositis-associated ILD: A randomized, open-label trial. Respirology 26：370-377，2021
26）Sugiyama Y, Yoshimi R, Tamura M, et al：The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease. Arthritis Res Ther 20：7，2018
27）Flaherty KR, Wells AU, Cottin V, et al：Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 381：1718-1727，2019
28）Raghu G, Remy-Jardin M, Richeldi L, et al：Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 205：e18-e47，2022
29）Nakajima A, Inoue E, Tanaka E, et al：Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol 39：360-367，2010
30）Kim EJ, Collard HR, King TE Jr：Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest 136：1397-1405，2009
31）Yamakawa H, Ogura T, Kameda H, et al：Decision-Making Strategy for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD). J Clin Med 10：3806，2021
32）Tsuchiya Y, Takayanagi N, Sugiura H, et al：Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J 37：1411-1417，2011
33）Enomoto N, Homma S, Inase N, et al：Prospective nationwide multicentre cohort study of the clinical significance of autoimmune features in idiopathic interstitial pneumonias. Thorax 77：143-153，2022
34）Kono M, Nakamura Y, Enomoto N, et al：Usual interstitial pneumonia preceding collagen vascular disease: a retrospective case control study of patients initially diagnosed with idiopathic pulmonary fibrosis. PLoS One 9：e94775，2014
35）Enomoto N, Oyama Y, Enomoto Y, et al：Differences in clinical features of acute exacerbation between connective tissue disease-associated interstitial pneumonia and idiopathic pulmonary fibrosis. Chron Respir Dis 16：1479972318809476，2019
掲載雑誌情報
